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ABSTRACT
Nasopharyngeal carcinoma (NPC) displays an Epstein-Barr virus (EBV) 
latency type II gene expression profile in the tumor cells, characterized by 
formation of viral proteins EBNA1, LMP1, LMP-2A/-2B and BARF1.  IgG and IgA 
humoral immune responses to these tumor-associated non-self antigens were 
analysed in a large panel of NPC patients (n=125) and regional controls (n=100) by 
three different approaches, i.e. indirect immunofluorescence assay (IFA) and 
immunoblot (IB) using baculovirus-expressed recombinant protein and Enzyme 
Linked Immunosorbent Assay (ELISA) using distinct synthetic peptide epitopes of 
these proteins, in particular focusing on the putative extracellular domains.   
Compared to the abundant IgG and IgA antibody responses to multiple 
lytic antigens and EBNA1 in NPC sera (15) in the same patients only low levels of 
antibodies to LMP1, LMP2A and BARF1 could be detected. Using IFA, NPC patients 
had low titer (1:25 - 1:100) IgG to LMP1 (81.2%), LMP2A (95.6%) and BARF1 
(84.8%) respectively, while IB showed such reactivity in 24.2%, 12.5% and 12.5% 
at 1:50 serum dilution, respectively. As positive control, IgG antibody responses to 
EBNA1 were found at high titer (>1:200) in 100% and 94.9% of NPC patients using 
IFA and IB, respectively. Few IgA responses were detected in NPC sera against the 
examined proteins, except for EBNA1 (81.8%  (IFA) and 56.5% (IB)). Healthy 
regional EBV carriers from the same region were virtually devoid of any antibody 
response to these EBV tumor-associated antigens, except for IgG to EBNA1. ELISA 
using synthetic peptides derived from different intracellular and putative 
extracellular domains of LMP1, LMP2A and BARF1 also yielded low and mostly 
negative IgG and IgA antibody responses in NPC patients. Fine mapping revealed 
that, when existing, most positive responses consist of IgG to intracellular C-
terminus of LMP1 (62.9%).  
Immunization of rabbits with synthetic peptides representing 
extracellular domain yielded specific antibodies serving as positive controls. 
Importantly, rabbit antibodies against putative LMP1 and LMP2 extracellular 
domains were shown to specifically stain extracellular domains of LMP1 and LMP2 
on viable EBV transformed cells.  These anti-loop antibodies were able to mediate 
complement-driven cytolysis on 50.4% and 59.4% of X50/7 and 35.0% and 35.9% 
of RAJI cell lines by anti-LMP1 loop-1 and -3 antibodies respectively, and nearly 
22% of both cell lines either by anti-LMP2 loop-2 or -5 antibodies.  
Data generated in this study demonstrate that EBV-encoded tumor-
associated antigens are at best marginally immunogenic for humoral immune 
responses in NPC patients. However, specific stimulation using exogenous peptide 
constructs may generate such antibodies, which can mediate killing activity 
through antibody dependent cytotoxicity. This opens options for peptide-based 
tumor vaccination in patients carrying EBV latency-II type tumors such as NPC.
INTRODUCTION
Epstein-Barr virus (EBV) is a human g-herpesvirus, that infects more than 
90% of the world population, and is associated with a spectrum of diseases, 
including infectious mononucleosis (IM) (19), Burkitt's lymphoma (BL) (13), 
Hodgkin's disease (22, 53), extranodal T/NK cell lymphoma (9, 51), immunoblastic 
B-cell lymphomas in immunocompromised individuals (44), gastric carcinoma 
(50) and nasopharyngeal carcinoma (NPC) (55).  
EBV persists for life in its human host after the primary infection and is 
well controlled by the host's immune system. Life-long immunosurveillance is 
reflected by the persistence of antiviral antibodies and virus reactive (cytotoxic) T 
cells (41).  Different sets of proteins expressed during EBV's lytic and latent life 
cycle induce qualitatively and quantitatively different immune responses (14, 21).  
Similar to other herpes viruses, EBV reactivation can occur in patients with 
immune defects or immune suppression reflected by aberrant IgG/M/A antibody 
responses (30). Importantly, EBV may cause a number of malignancies of 
lymphoid and epithelial  origin in both immunosuppressed and 
immunocompetent individuals, which are also reflected by aberrant antibody 
responses to EBV. 
In the neoplastic cells of these malignancies, several EBV latent gene 
products are expressed corresponding to the latency type.  NPC is one of the latency 
type II tumors and is characterized by expression of EBNA1, LMP1, LMP-2A/ -2B 
proteins (3, 20, 24) with co-expression of the epithelial oncogene BARF1 (2, 11, 
43). In view of potential immunogenicity of virus-encoded “nonself” proteins, it is 
surprising that LMP1, LMP2 expressing tumors occur in immunocompetent 
individuals, who are considered to have the capacity of mounting an effective 
immune response to these “non-self” proteins.  
+ CD8 T cell responses to EBV latent antigens are skewed towards 
immunodominant epitopes derived from the EBNA3A, 3B, and 3C protein family.  
Accompanying subdominant responses map to additional epitopes from the same 
EBNA3 family or from LMP2, and much less often to epitopes from EBNA2, EBNA-
LP, or LMP1 (21, 25, 37).  Only limited data are available for T cell responses to 
+BARF1 (29).  Early work on EBNA1 as CD8 T cell target showed that the internal 
250 amino acid glycine-alanine repeat (GAr) protects the endogenously expressed 
+EBNA1 from CD8 T recognition (27), as consequence from GAr-mediated 
interference with proteasomal degradation (8). EBV has multiple evasion 
+strategies in establishing and maintaining latency in the face of a CD8 T cell 
response by switching-off antigen expression in those cells constituting the latent 
reservoir (48), by inducing T-cell anergy (12) or Treg's (28) or by active 
interference with antigen processing and presentation during lytic replication 
(52, 54).
EBNA1 is well recognized as a major target for humoral immune 
responses. However, only few studies addressed the role of LMP1 and LMP2 
proteins as targets for humoral immune responses in detail. Antibody reactivity to 
LMP1 has been described in different EBV-related patient populations, including 
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NPC, Hodgkin Disease, mononucleosis, and Burkitt Lymphoma patients, using 
different techniques, such as ELISA, immunoblot, and migration inhibition assays 
(4, 26, 30, 31, 36, 42, 45).  Previous studies indicated that LMP1 is a protein with a 
low immunogenicity for the humoral immune response in humans. In NPC only 
7.5% (3/40) patients had low serum levels of LMP1 directed antibodies, whereas 
antibodies to LMP2A/2B were detected at low titer in about 40-60% of NPC sera 
from different ethnicity (26, 30).  Structurally, LMP1 and LMP2A/B are suggested 
to protrude from the cell surface via several conserved small loop domains 
connecting the transmembrane helices (36). However these loop-domains have 
not been studied as target for humoral immune response to date.  Importantly, 
such anti-loop antibodies may have potentially important function in targeting 
complement and/or FcR-bearing killer cells to LMP1, 2 expressing tumor cells. A 
prior study of antibody to BARF1 in sera with EBV-associated diseases including 
NPC suggested that the BARF1 protein may serve as target on EBV-infected cells 
for antibody dependent cytotoxicity (ADCC) (47). However, this study has not been 
confirmed and recent data indicate that BARF1 is rapidly and completely secreted 
from the EBV positive cells, making it a disputable target for ADCC (10, 43).
In this study, we evaluate in detail antibody responses to EBV-tumor 
associated antigens LMP1, LMP2 and BARF1 in NPC patients compared to healthy 
EBV carriers.   We further developed specific antibodies to the putative LMP1 and 
LMP2 extracellular loop domains and evaluate whether such antibodies can 
mediate complement killing of the LMP1 and LMP2 expressed cell lines, e.g. RAJI 
and X50/7.  The results may provide a basis for understanding EBV tumor immune 
escape and indicate options for a novel approach to target extracellular domains of 
LMP1 and LMP2 expressing tumor cells.
MATERIAL AND METHODS
Sera from NPC patients and Healthy EBV Carriers.  Serum panels from 
histologically confirmed NPC patients (overall n=125) were collected from 
department of Ear, Nose and Throat (ENT), Dr. Sardjito General Hospital, 
Yogyakarta.  NPC sera were taken on the first visit of patients to the clinic, prior to 
treatment.  NPC staging was done by ENT examination and CT-scan and classified 
according to the 1996 criteria established by UICC (Union International Cancer 
Control). Sera from healthy EBV carriers (overall n=100) were obtained from the 
local red-cross blood bank. All sera were extensively analysed for reactivity to 
multiple EBV-encoded lytic cycle proteins in prior studies (14, 15, 39, 40).  NPC 
tissues from available formalin fixed paraffin embedded NPC tumor biopsies were 
examined the EBV status by EBER in situ stining (DAKO, PNA) and analysed the 
expression of LMP1 using S12 or OT21C MoAbs based immunohistochemistry 
(31). 
Cell culture.  The EBV positive RAJI Burkitt Lymphoma cell line, the in vitro EBV 
transformed B cell line X50/7, BJAB-LMP1 (kind gift of M. Rowe) and Daudi-LMP1 
(kind gift of P Busson) were cultured in RPMI-1640 medium comprising 25mM 
Hepes and glutamin (Sigma, St.Louis, USA), 10% fetal calf serum (FCS, Hyclone, 
Perbio, Sweden), 100 IU/ml penicillin and 50 g/ml streptomycin (p/s) at 37°C in a 
humidified 5% CO  atmosphere.  Both cell lines express relatively high levels of 
LMP1 and LMP2 (1, 33). Insect cells were cultured as described below. 
The BJAB-LMP1 cell is originally from EBV negative cell line BJAB 
transfected with LMP1 expression vectors.  The LMP1-transfected clones of BJAB 
were established using a tetracycline-regulated vector system and were 
maintained in culture medium containing 1.5 mg/ml G418, 0.5 mg/ml hygromycin 
B, and 1 g/ml tetracycline. Tetracycline withdrawal induced LMP1 expression as 
previously described (16). 
Recombinant proteins.  The Baculovirus constructs expressing full-length LMP1, 
LMP2A, BARF1 and EBNA1 without the GAr domain were made under control of 
6the polyhedrin promoter (32, 33).  Sf9 cells were cultured to the log phase (1 x 10  
cells/mL) and infected with one of the Baculovirus constructs. A high dose of 1-5 
PFU/cell was used for recombinant protein production and cells were harvested at 
48 hours post infection (pi). For immunofluorescence experiments infection at 1 
PFU/cell for 48 hours was used leaving about 50% uninfected cells in the 
preparation, which were used as specificity control. Insect cells were cultured in 
serum-free SF900-II medium at 28ºC.  
EBV synthetic peptides. Immunodominant epitopes on EBV proteins were derived 
by computer prediction techniques, as described by Modrow and Wolf (36), using 
high scores for hydrophilicity, flexibility, and b-turn probability. Peptides 
mimicking different domains of LMP1, LMP2 and BARF1 proteins were 
synthesized with a peptide synthesizer (433 A; Applied Biosystem, Foster City, 
CA). Peptides representing putative extracellular loop domains of LMP1 and LMP2 
were also synthesized as circular peptides by inserting two cysteine residues at the 
ends forming a S-S bridges upon oxidation (49). Most peptides were extended at 
the N-terminus with additional lysine residues for improving solubility and 
coupling options. All peptides were purified in reverse phase high performance 
liquid chromatography (Beckman System Gold, Mijdrecht, The Netherlands).  
Peptide coupling to carrier proteins KLH or TTd was performed by standard 
techniques using commercial reagents (Sigma, St.Louis, USA). Peptide 
denomination and amino acids sequences are listed in table 1. 
Monoclonal and polyclonal antibodies.  Monoclonal (MoAb) and polyclonal 
(PoAb) antibodies were obtained by immunization of mice and rabbits with 
synthetic peptides or purified recombinant EBNA1, LMP1, LMP2 and BARF1 
proteins expressed in insect cells. Female Chinchilla rabbits were immunized with 
either keyhole limpet hemocyanine (KLH) or tetanus toxoid (TTd) conjugated 
synthetic peptides or isotachophoresis isolated recombinant proteins (30). Before 
immunization pre-serum of each rabbit was drained from the ear.  For primary 
immunization 1 mg antigen was mixed well with 1 ml Freunds Complete Adjuvant 
2
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SDS-PAGE and western blot analysis.  Recombinant proteins were solubilized in 
standard Laemmli sample and boiled for 5 min. and separated in 10% acrylamide 
gels using the Mini Protean II system (BioRad, Hercules, USA) under reducing 
condition.  Polypeptides were transferred from the gel onto 0.2 mm nitrocellulose 
(Schleicher & Schuell, Hertogenbosch, the Netherlands) by Western blotting (Mini-
Trans blot cells, BioRad). After transfer, nitrocellulose sheets were washed with H O 2
and dried between filter paper and stored at 4°C until use.  Marker proteins (Bio-
Rad Low MW marker) were run on the side to indicate the molecular weight of 
polypeptides.  Non-specific binding sites were saturated with blocking buffer (5% 
horse serum and 5% non-fat dry milk (Campina, Eindhoven, the Netherlands) in 
PBS pH 7.2) followed by incubation with Moab or PoAb at appropriate dilutions or 
sera at different dilutions made in blocking buffer.  After washing with PBSt, specific 
bound IgG and IgA were detected with horseradish-peroxidase (HRP)-conjugated 
secondary antibody (Dako, Golstrup, Denmark) in blocking buffer and HRP-activity 
was visualized by using 4-chloro-1-naphtol (15).  
Synthetic Peptide ELISA.  Standard microtiter plates (Biobasic, Canada) were 
coated overnight at 4°C with 135 ml of one of the peptides in a concentration of 1 
g/ml in 0.05M carbonate buffer, pH 9.6.  Excess coating fluid was removed and non-
specific binding sites were blocked subsequently for 1 h with 200ul/well of 
PBS/3% BSA at 37C. Further incubations were performed for 1 h at 37°C followed 
by four washes with PBSt.  Human sera were diluted 1:50  in ELISA sample buffer 
(PBSt; 0.1% Triton-X100, 1% BSA), followed by washing and incubation with HRP-
labeled rabbit anti-human IgG (1:3000) and IgA (1:2000) (DAKO, Copenhagen) 
diluted in conjugate buffer (PBSt; 0.1% (v/v) Triton-X100, 1% BSA and 2% normal 
rabbit serum). Peptide-specific Moab or PoAb were diluted in ELISA sample buffer 
and detected with rabbit anti-mouse or swine anti-rabbit HRP conjugates (Dako) 
(both at 1:1000), respectively. HRP activity was detected using 3,3',5,5'-
tetramethylbenzidine (TMB) (BioMerieux, Boxtel, The Netherlands) and the 
reaction was stopped by adding 1M H2SO4.  The optical density was determined at 
450 nm (Anthos 2001 reader, Anthos Labtec, Austria).
Membrane immunofluorescence on viable cells.  Log-phase grown RAJI, X50/7, 
Daudi-LMP1, BJAB-LMP1 and BJAB cell suspensions were used and all incubations 
were performed on ice with pre-cooled solution unless mentioned otherwise.  
Prior to immunofluorescence, lymphoprep purification was performed to remove 
6dead cells from the suspension.  Cells were transfered to FACS tubes at 0.5 x 10  
cells/ 100 L staining buffer [Hank balanced salt solution (HBSS); 0.1% (w/v) NaN ; 
1.0% (w/v) BSA, fraction V)].  Subsequently, appropriate dilutions of PoAb anti-
LMP1 loop-1 and -3 and LMP2 loop-2, and -5 were added and incubated for 20 
minutes.  Following two washes with staining buffer, fluorescein isothiocyanate 
(FITC)-labeled swine anti-rabbit Ig (1:100) in FACS buffer was added and incubated 
for 20 minutes. For confocal microscopy cells were washed in HBSS, cyto-
centrifuged onto glass slides and counterstained for 5 min. Microscopic analysis 
was done using a Leica TCS confocal microscope (Leica, Cambridge, England) and 
3
(FCA) and injected subcutaneously and intramuscularly. Each rabbit was coded as 
k followed with numbers (xx).  Approximately 30 days (+/-1 day) after primary 
immunization 5 ml blood was drawn and coded as kxx/-1. First, second and third 
immunizations with Freunds incomplete adjuvant (FIA) were given with an 
interval of approximately 1 month. Booster blood samples (kxx/ -2, -3, 4, or 5) 
were taken 10 days after booster injection [Aarbiou & Middeldorp, unpublished]. 
Production of monoclonal antibodies to various intracellular domains of LMP1 and 
LMP2 was described before (18, 30, 33), MoAbs to N- and C-terminal domains of 
BARF1 were made in-house by standard procedures [Klarenbeek and Middeldorp, 
unpublished].
Immunofluorescent (IF) staining on fixed recombinant antigen-expressing cells. 
Cytospins were made with Sf9 cells either infected with wild type (wt) baculovirus 
or recombinant baculovirus.  Slides were fixed in cold (-20ºC) acetone and pre-
incubated in PBS containing 2% fetal calf serum (PBS/2%FCS) for 10 min.  All 
washings were done three times in PBS/0.05% Tween-20 (PBSt).  Antibody 
dilutions were made in PBS/2% FCS and incubated at RT.  MoAbs were diluted in 
100 - 1000 times and human sera were used in a 1:25, 1:50, 1:100 and 1:200 and 
incubated for 1 h unless stated otherwise.  After washing, the slides were 
incubated for 30 min with FITC-labeled rabbit anti-mouse Ig or anti human IgG 
secondary antibodies (DAKOPATTS, Denmark). Finally slides were counterstained 
for 5 min. with a 1:1 mix of DAPI and Evans blue or 1:500 ToPro 3 (Partec, The 
Netherlands) washed, dipped with mounting fluid Vectashield, sealed with a 
coverslip and evaluated with a Leica DMRB fluorescence microscope (Leica, 
Cambridge, England).
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Overall, IF results with NPC sera showed rather low (most 1:25 - 1:100) 
IgG reactivity to acetone-fixed rLMP1, rLMP2A and rBARF1 being detectable in 
81.2%, 95.6% and 84.8% of tested sera, respectively, whereas IgG to rEBNA1 was 
present at higher titers (> 1:200) in 100% of the sera (n=32) (Figure 1J). In 
results were digitally stored.  For FACS analysis, 
RESULTS
Humoral immune responses in NPC patients and healthy EBV carriers to 
recombinant EBV-encoded Tumor Associated Protein.  In this study, we explore 
the antibody responses of NPC patients to individual recombinant proteins LMP1, 
LMP2 and BARF1. Antibody responses to the individual proteins were analyzed by 
indirect immunofluorescence (IF) and immunoblot (IB) techniques.  Sf9 insect 
cells infected with recombinant Baculovirus expressing full-length LMP1, LMP2A 
and BARF1 were used as antigen (rLMP1, rLMP2A, rBARF1, respectively), mainly 
as described previously (30, 32, 33). A low MOI was chosen to leave 40-60% Sf9 
cells uninfected, serving as internal specificity control in each experiment. 
Recombinant EBNA1 deleted of the GAr (rEBNA1) was used as positive control and 
all sera and MoAbs were analysed in parallel on Sf9-cells infected with wild type 
Baculovirus (wtBac). Expression of LMP1, LMP2A, BARF1 and EBNA1 in the 
infected Sf9 cells was confirmed by staining with specific MoAbs to the individual 
EBV proteins (Figure 1).  Human antibody staining was interpreted with the MoAb 
staining pattern as reference. 
the cells were washed three times 
with staining buffer and resuspended in 100 mL propidium iodide solution.  Data 
acquisition was performed on FACScalibur flow cytometer (BD Biosciences, 
Franklin Lakes, NJ).  Cell staining with anti- M antibody (Dako) served as positive 2
control.  
MTT assay.  To evaluate the cytolytic capacity of anti-LMP1 and -LMP2 loop-
specific antibodies, complement cytotoxicity studies were performed with MTT 
read-out (Cell Proliferation Kit I, Roche, Germany) using EBV, LMP1, 2 positive 
RAJI and X50/7 cell lines and appropriate controls.  All incubations were 
performed at 37ºC and 5% CO .  Prior to the experiment, lymphoprep purification 2
4was performed to remove dead cells.  Cells were placed on a 96 well plate at 10  cells 
/25 ml per well.  Antibody anti-loop-1 and -3 LMP1 and anti-loop-2 and -5 LMP2 
(1:3, 1:10, 1:50 and 1:250) were added, followed by the addition of 50 ml 30 times 
diluted rabbit complement (Innovative Research, USA) and incubated for 2 hrs. As 
controls, cells were incubated with rabbit preserum or beta-2 microglobuline.  
Subsequently 5 ml MTT labeling reagent was added.  After 4 hrs, 50 mL 
solubilization reagent was added and after overnight incubation, the optical 
density was determined at 550-600 nm.  Percentage of dead cell was calculated by 
using the formula below.  
Percentage (%) cell death:
OD of untreated cells (blank)  OD of treated cells 
                                                                                                          X 100%
                    OD of untreated cells (blank)  
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Figure 1.
Antibody detection by indirect immunofluorescence of acetone-fixed Sf9 cells infected with Baculo-EBNA1 (A, B), 
Baculo-LMP1 (C, D), Baculo- LMP2A (E, F), Baculo-BARF1 (G, H) and WT-baculo (I). Cells were incubated with OT1X 
(1:200, mouse anti-EBNA1) (A), OT21C (1:100, mouse anti-LMP1) (C), 14B7 (1:100, rat anti-LMP2A) (E), K150-3 
(1:100, rabbit anti-BARF1) (G), and serum of NPC patients containing antibodies anti-EBNA1, LMP1, LMP2A and 
BARF1 (B, D, F, H respectively). Sf9-recombinant WT-Bac protein served as negative control incubated with either 
Mo/PoAbs or NPC serum (I). Similar pattern was observed as Baculo-BARF1 incubated using K150-3, when the cells 
were incubated with mouse MoAb 4A6 (mouse anti BARF1). (J) Bar charts summary of antibody responses of NPC 
sera toSf9 cells infected with Baculo- EBNA1, -LMP1, -LMP2A and -BARF1 using IFA. For an indication of the level of 
antibody response, NPC sera were examined at various dilutions.
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general, observed background reactivity with uninfected Sf9 cells and Sf9-wtBac 
was minimal and, when present, wt-Bac staining pattern could be discriminated 
from EBV antigen-specific staining. In simultaneous IF analysis, IgA reactivity to 
rLMP1, LMP2A and BARF1 was observed at even lower titer (< 1:25) and at lower 
frequency in 40.9%, 54.5%, and 59.0% of NPC sera respectively.  IgA to rEBNA1 
was observed at slightly higher titer (1:100) in 81.8% of the sera (n=22) (data not 
shown).
Subsequently, to reveal potential immune responses to possible linear 
epitopes in fully denatured EBV tumor proteins, a set of NPC sera (n=123) was 
tested for IgG and IgA reactivity by IB analysis at dilutions of 1:50 using lysates of 
Sf9 cells expressing either rLMP1, rLMP2A, rBARF1 or rEBNA1.  Figure 2A-C show 
that control MoAbs OT21C, 14B7 and 4A6 recognize clear bands at 63kD (LMP1), 
54kD (LMP2a) and 30kD (BARF1). In contrast to IF, IB analysis revealed very low 
IgG responses to LMP1, LMP2A and BARF1 indicated by weak intensity of the 
specific protein band in 24.2%, 12.5% and 12.5% NPC patients, respectively. In 
general EBV-protein specific staining by IB was only detectable using the lowest 
dilution (1:50), if detectable at all.  IgG reactivity to rEBNA1 was observed at 94.9% 
of NPC patients (Figure 2D), and showed similar clear band at 55kD as revealed by 
OT1X Ab (figure not shown).  None of NPC patients had detectable IgA response to 
the LMP1, LMP2A and BARF1 by IB analysis, but a weak IgA response to EBNA1 
was observed at 56.5% NPC patients. These data indicated that NPC patients, who 
have high-level antibody reactivity to multiple lytic cycle antigens and EBNA1 (14, 
LMP1 expression and antibody reactivity in NPC cases.  No relation was found 
between LMP1, LMP2 and BARF1 responses (when present) with TNM stage of the 
tumor.  In cases analyzed for serological responses to LMP1 by IFA (n=32) or IB 
(n=125) we also detect the presence of LMP1 at the tumor level using MoAb base 
immunohistochemistry.  Results are shown in table 3A and 3B.  Overall 80% of the 
NPC were found to LMP1 expression using immunohistochemistry.  In cases 
having antibody reactive with LMP1 by IFA has positive correlation with LMP 
expression on the tumor (68.8% concordance), but by IB has negative correlation 
(33.6% concordance) (table 3). IFA and IB may detect different epitopes, which is 
related to the level of denaturation of the antigen used, being minimal in IFA aceton 
fixation, and maximal in IB SDS boiling.  Therefore we decided to analyse this 
option in more detail.  The functional importance of detecting Ab-responses to 
LMP1 and LMP2 conformational domain will be of particular interest when 
expressed on the tumor cell surface.
Antibody Responses to defined extracellular peptide-epitopes of and LMP1, 
LMP2 and BARF1.  To more precisely study the epitope specificity in the sera of NPC 
patients, defined synthetic peptides representing putative extracellular domains of 
LMP1, LMP2 and BARF1 were created and used as antigen in ELISA.  Cytoplasmic 
peptide epitopes of LMP1 and LMP2 and extracellular domain of BARF1 were 
selected for having high scores for hydrophilicity, flexibility and -turn probability as 
15), are largely lacking potent antibody responses to tumor associated membrane 
antigens LMP1 and LMP2A, as well as BARF1, as examined with intact full length 
recombinant proteins.
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Figure 2.
Immunoblot analysis of SF9-baculo expressed recombinant proteins stained with monoclonal, mono-reactive 
polyclonal antibodies and NPC sera. 
(A) Baculo-LMP1 strips, (B) Baculo-LMP2A strips, (C) Baculo-BARF1strips, stained with Mo/PoAbs specific to the 
protein (line 1 for each protein strip) and stained with NPC sera (line 2-the rest for each protein strip). (A-OT21C) 
Baculo-LMP1 strip stained with OT21C MoAb showing band on 63kD, (B-14B7) Baculo-LMP2A strip stained with 
14B7 PoAb showing band on 54kD, (C-K150-3) Baculo-BARF1 strip stained with K150-3 PoAb showing band on 30kD. 
(A1 - A23) Baculo-LMP1 strip stained with NPC serum (1:50), (B1-B23) Baculo-LMP2A strip stained with NPC serum 
(1:50), (C1-C19) Baculo-BARF1 strip stained with NPC serum (1:50). (D) Bar charts summary of antibody responses 
of NPC sera toSf9 cells infected with Baculo-EBNA1, -LMP1, -LMP2A and -BARF1 using IB. For anindication of the level 
of antibody response, NPC sera were examined at 1:50 dilutions.
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Described before (30, 35, 36).  In addition, for LMP1 and LMP2 synthetic peptides 
stwere also created representing the extracellular loop 1 and 3 (connecting the 1  to 
nd th th2  and 5  to 6  transmembrane helix, respectively) and loop 2 and 5 (connecting 
rd th th ththe 3  to 4  and 9  to 10  helix respectively), respectively (Figure 3A & 3B). 
Synthesis of cytoplasmic peptide domains of LMP1 have been described previously 
(30).  For LMP1 we used peptide domain in circular conformation to more closely 
mimick the in vivo structure.  Circular peptides were created by oxidation of the 
sulfide bridge in peptides OTP 405 and OTP 407 (Table 1) (49). These peptides 
were used as antigens in indirect ELISA. Epitope-specific antibodies were 
generated by rabbit immunization using carrier proteins conjugated to the 
peptides. These newly developed antibodies were used as positive control in the 
ELISA (Figure 3).  All human sera used were strongly responsive to VCA-p18 and 
EBNA1 synthetic peptides as described before (14).
Analysis of LMP1, 2 and BARF1 peptide-epitope specific antibody 
response by ELISA did not show major differences between NPC patients and 
healthy EBV carriers.  When detectable, positive responses were marginal in most 
cases and the most significant response  (62.9% positive) in NPC patients is 
confined to IgG against the intracellular C-terminus of LMP1 (Figure 3C).  Overall 
analysis is depicted in table 2.  Table 2A shows the number of donors and patients 
having IgG responses to the individual peptides of tumor-associated EBV proteins.  
IgG responses to LMP2 in healthy EBV carriers were lower compared to responses 
to LMP1 and BARF1.  There was no difference in LMP1 loop-peptide responses 
when using circular (created by S-S bridge oxidation) or linear peptides (data not 
shown). None of healthy EBV carriers had IgG responses to LMP2 loop peptides.   
Responses to C-terminus and N-terminus LMP2 are found only in 2.0% and 1.8% 
Table 2A. Positive IgG responses (%) in NPC and healthy EBV carriers to LMP1, LMP2 and 
BARF1 peptides. 
Table 2B. Positive IgA responses (%) of NPC and healthy EBV carriers to LMP1, LMP2 and 
BARF1 peptides.
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Figure 3.
Structural representation of LMP1 and LMP2A molecule in the plasma membrane and IgG responses of NPC 
patients and healthy EBV carriers to peptide epitopes of LMP1 and LMP2A. 
Both proteins contain an intracellular N and C-terminus. (A) LMP1 is characterized by three short extracellular loops 
connecting the six membrane-spanning segment. (B) LMP2 has 6 short extracellular loops, connecting 12 membrane 
spanning domains. (A) Anti-C terminus, -N terminus, -loop-1 and -loop-3 of LMP1 and (B) anti-C terminus, -N 
terminus, -loop-2 and -loop-5 of LMP2 specific antibodies were generated by rabbit immunization.  Polyclonal 
antibodies generated from rabbit immunization with the LMP1 peptide showed strong specific reactivity to each 
epitopes: (C) K49-3 to the C-terminus LMP1, (D) K48-3 to the N-terminus LMP1, (E) K31-3 to the Loop1 and (F) K56-3 
to the Loop-3. Polyclonal antibodies generated from rabbit immunization with the LMP2A peptides showed strong 
specific reactivity to each epitopes: (G) K41-3 to C-terminus, (H) K42-3 to N terminus, (I) K47-3 to Loop-2 and (J) K43-
3 to Loop-5. NPC: nasopharyngeal carcinoma, HC: Healthy EBV carrier.
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of healthy EBV carriers, respectively.  About 5% of healthy EBV carriers had IgG 
response to subfragments of LMP1 and BARF1.  Table 2B shows the number of NPC 
patients and healthy EBV carriers with IgA responses to peptides of LMP1, LMP2 
and BARF1.  IgA responses are lower as compared to IgG reponses, and most of the 
IgA responses in NPC patients can also be addressed the C-terminus of LMP1 
(27.4%).  
Accessibility of LMP1 and LMP2 loop domains on viable EBV transformed cells.  
LMP1 and LMP2 are transmembrane proteins, with six or twelve membrane-
spanning domains, respectively, connected by intracellular and extracellular loops. 
The extracellular loop domains are potential targets for functional immune 
responses, and may mediate killing of EBV transformed cells via complement 
dependent cytotoxicity (CDC) or killer cell (ADCC) dependent cytotoxic pathways.  
To study the accessibility of the extracellular loops of LMP1 and LMP2 on viable 
cells, we evaluated specific antibody recognition of these proteins expressed on 
viable RAJI, X50/7, Daudi-LMP1, BJAB-LMP1 and BJAB cell lines by FACS analysis 
and confocal microscopy.  All cell lines except BJAB cells were positive for LMP1 
and LMP2A mRNA as determined by reverse transcription PCR and by intracellular 
protein staining.  For the latter, permeabilized cells were treated with monoclonal 
antibodies OT21C and 14B7, recognizing the intracellular epitopes of LMP1 and 
LMP2A respectively (data not shown). Both LMP1 and LMP2A revealed a 
heterogeneous intracellular staining pattern between individual cells of a cell 
population as described before (26, 42). The presence of LMP1 and LMP2A loop 
domains on the surface of those cell lines were detected by FACS analysis using 
anti-loop specific antibodies for LMP1 loop 1 and 3 and LMP2 loop2 and 5.  LMP1 
clearly expressed on RAJI and X50/7 (5-15% of the cells), but clearly negative with 
Namalwa and BJAB.  Figure 4 shows a fine patch-like staining observed on RAJI 
cells with soluble loop1 and 3 LMP1 and BJAB as negative control and FACS analysis 
of RAJI cells using similar antibodies.  On cells artificially expressing LMP1 (Daudi-
LMP1 and BJAB-LMP1) by vector transfection much higher staining was seen (20-
50%).  LMP2 best expression was seen on loop2 on X50/7 cells (data not shown).  
Rabbit antibody against b2M reacted with >88% of all cell lines.  Staining pattern 
of individual viable cells was determined by confocal microscopy, revealing a 
heterogenous staining pattern similar to the cytoplasmic staining patterns, with 
some cells being negative, and others being positive and showing a patch-wise 
distribution of LMP1 and LMP2 related epitopes. This is the first demonstration 
that extracellular LMP1 and LMP2 related loop domains, can potentially function as 
targets for antibody-based therapy.
Complement lysis by anti-LMP1 and -LMP2 loop-specific antibodies.  Since 
LMP1 and LMP2 are expressed in multiple EBV tumors, including NPC, targeting of 
the extracellular domains may have therapeutic potential. We demonstrated that 
immunization of rabbits using synthetic peptides mimicking the extracellular loop 
domains of LMP1 and LMP2 could generate specific anti-loop antibodies. This 
approach might be applicable to humans as well, aiming for therapeutic 
Vaccination. Considering this option, we evaluated the functional activity of the 
anti-loop antibodies and analysed complement mediated lysis using RAJI and 
X50/7 cell lines.  Figure 5 shows that by 4 hr complement lysis 35%, 35.3%, 22.4% 
and 22.3% of RAJI cells were killed by anti-LMP1 loop 1 and 3 and anti-LMP2 loop 2 
and 5 antibodies respectively, and 50.4%, 59.4%, 22% and 22.7% of X50/7 as 
measured by MTT assay.  Killing potential of each antibody depend upon dilution 
(Figure 5).  No cell lysis was observed by pre-serum obtained from these rabbits 
and no lysis was observed with Namalwa or EBV negative Ramos or BJAB cell lines.  
Using â2M as target closely to 80% cells were lysed by rabbit anti-â2M in this assay. 
These results demonstrate that newly developed anti-loop antibodies can 
functionally target extracellular domains of LMP1 and LMP2, which may have 
important therapeutic implications.
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Figure 4.
Accessibility of extracellular loops of LMP1 on viable RAJI and BJAB cells as determined by specific anti-loop 
antibodies.
(A) In all experiments EBV negative BJAB cells produced a negative membrane staining with the LMP1 and LMP2 
loop-specific sera. (B) As positive control, RAJI and BJAB cells showed more than 88% positive staining using anti--
2microglobulin. (C, D) A fine patch-like staining was observed on the surface of RAJI cells, with anti-LMP1 loop-1 and -
3 specific antisera (C, D respectively). (E) Anti-LMP1 loop-1, -3 specific antisera produced a similar patch-like 
staining on stably transfected BJAB cells induced for LMP1 expression during 24 hours from a teracyclin regulated 
promoter. (F) Antisera to LMP2 loop-2 and -5, produced a similar patched staining pattern on X50-7 cells, with 
somewhat larger patches than observed for LMP1. (G) Flow cytometry histogram comparing the levels of accessibility 
of anti loops LMP1 on Raji cells. Staining obtained with the indicated anti loop-1 (purple line), anti loop-3 (blue line) 
and using anti b2M as positive control (green line). Background staining with pre-serum shows an irrelevant 




Individuals with EBV infection develop antiviral immune responses to a 
wide variety of EBV proteins and epitopes.  Monitoring of anti-EBV antibody 
responses has yielded useful applications for diagnosis in various EBV-associated 
diseases, such as NPC.  Elevated antibody titers to EBV antigen e.g. early antigens 
(EA), viral capsid antigens (VCA) and the EBNA1 protein are frequently found in 
NPC patients and are relevant as diagnostic and prognostic markers (5, 14, 15, 23, 
38, 39).  However most of the EBV antigens used for diagnosis are not expressed in 
tumor cells, but are derived from sporadic cells entering the lytic stages infection 
accompanying the malignant process. 
Besides EBNA1, which is universally expressed in all EBV tumor cells, 
latent EBV proteins such as LMP1 and LMP2 are regularly detected in NPC (20, 24).  
In this tudy we could detect LMP1 expression about 80% of the case analyse 
(n=125), but we did not have access to the LMP2-reactive antibodies used by 
Heussinger.  In addition, recent studies revealed the expression and secretion of 
BARF1 protein in NPC and gastric cancer in absence of lytic gene expression   Due 
to the expression of non-self viral proteins in the NPC tumor cells, the possibility 
appears that these proteins might become targets of immune response, aiding in 
protection.  Previous studies demonstrated that EBNA1, LMP2A and to a lesser 
extend LMP1 can elicit virus-specific cellular immunity and are proposed as 
antigen for immunotherapy (6, 7, 21, 46). However, informations on humoral 
immune responses to LMP1, LMP2A and BARF1 antibodies is rather limited (17, 
26, 30, 47). In our study using IF-analysis on acetone-fixed recombinant proteins 
expressed in insect cells, IgG antibodies to LMP1 and LMP2 were found in a 
significant number of NPC patients (81.2 % and 95.6%, respectively), albeit in low 
titers, but hardly in controls.  
IgG response to BARF1.  
Antibody responses against BARF1 protein have been studied before using sera 
from chronic and acute IM and NPC patients (47). Using transduced RAJI cells they 
demonstrated significant ADCC reactivity to BARF1-expressing RAJI cells in sera 
from NPC patients.  However no study has yet confirmed antibody responses to 
BARF1 to strengthen these findings. In fact, BARF1 seems to be rapidly and 
completely secreted by BARF1 expressing cells, leaving little protein in or on the 
cells for detection (10, 43). The role of anti-BARF1 immune responses remains to 
be further established.
Immunoblotting confirmed the low-level antibody responses, being 
detectable at 24.2%, 12.5%, and 12.5% of NPC patients for LMP1, LMP2 and 
BARF1, respectively.  The lower response rates compared to IF-analysis may be 
due to the fact that antigens prepared by SDS-PAGE may have lost certain 
conformational epitopes. Again anti-EBNA1 antibodies were clearly detected, 
confirming the immunodominance of EBNA1. IgA-specific analysis showed 
similar low responses to LMP1, LMP2A and BARF1, but again clearly detectable 
responses to EBNA1. This demonstrates a lack of local mucosa-specific responses 
to the tumor-associated latent EBV membrane antigens, hinting at specific defects 
in their presentation to the immune system. These observations are clearly in 
contrast to the responses to the marginally expressed but highly immunogenic 
lytic antigens, to which abundant IgG and IgA antibody responses are detectable in 
the same NPC patients (14, 15, 39).  Importantly, most (80%) NPC cases analysed 
showed LMP1 expression.  We found a positive correlation between LMP1 
expression and Ab-resposes using IFA analysis, but a negative correlation when 
using IB (table 3).  This may suggest that conformational epitopes, which are more 
reactive by IFA may triggered in LMP1 positive tumor cases, whereas antibodies to 
linear (denatured) LMP1 are triggered differently (i.e. by cross presentation).  Our 
finding in NPC differe from previous observation in HD, where LMP1 antibodies 
were most prevalent in EBV negative cases (31).  
The data from this study using EBV-recombinant proteins showed that 
NPC patients only have weak humoral immune responses to LMP1, LMP2 and 
BARF1. However the potential importance of LMP1 and LMP2 as targets for 
immunotherapy, prompted us to further analyze the presence of antibodies in NPC 
This confirms and extends previous studies that used 
smaller numbers of patients and controls (17, 26, 30).  In all samples tested, the 
responses were low compared to IgG-EBNA1. By using a similar method we found 
that 84.8% NPC patients have a detectable but low titered 
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Figure 5.
Complement mediated cell lysis. RAJI cells were incubated with a dilution series of anti-loop antibodies (3x, 10x, 
50x and 250x) and 30 times diluted complement solution. Percentage cell death is plotted against antibody dose. In 
3x dilution of anti-loop antibodies, approximately 49% RAJI cells were killed by anti-loop-1 and -3 LMP1 and 35% 
by anti-loop-2 and loop-5 LMP2A. Similar results or even higher killed-cells were obtained in other EBV carrying LCL 
lines but not in Namalwa, an EBV positive cell lines with LMP1 and LMP2 negative. Anti-B2M antibody was taken as 
a positive control, and used at larger dilution (1:5000) and therefore is not reaching >80% lysis. Preserum was used 
as negative control and to distinguish with specific binding of specific antibodies.
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patients directed to defined extracellular epitopes of LMP1, LMP2 and BARF1 in the 
form of synthetic peptides.  No such information was available yet, and, in fact, the 
extracellular accessibility of domains of LMP1 and LMP2 has not been clearly 
demonstrated before. Therefore we extended our previous studies and explored 
responses to defined peptide epitopes mimicking these domain (30).  In rabbits, 
polyclonal epitope-specific antibodies were developed directed against distinct 
domains of LMP1, LMP2 and BARF1. These antibodies, having a high affinity for 
their epitopes in denaturated as well as in the native conformation on viable cells, 
were used as positive controls. Using these anti-loop antibody reagents we were 
the first to demonstrate the presence and functional accessibility of extracellular 
loop domains of LMP1 and LMP2, opening option as targets for therapeutic 
applications (34).  However, in naturally EBV infected NPC patients and healthy 
EBV carriers these LMP1 and LMP2 loop domains seem to evade from immune 
recognition, as anti-loop antibody responses are mostly negative (Table 2). The 
results of peptide-specific analysis confirm the presence of some antibody 
responses to the intracellular C- and N-terminal domains of LMP1 and LMP2, 
although only at a low levels (Figure 4B).  Intrinsic properties of LMP1 and LMP2 
and their short existence in the plasma membrane may be responsible for the low 
immunogenicity.   On the other hand, this study shows that LMP1 and LMP2 
antibodies specifically directed against the extracellular loop domains can be 
generated by immunization of rabbits using related peptides and these antibodies 
can activate the complement system to kill LMP1 and LMP2 expressing cells.  
X50/7 cells can be killed by complement (50.4% and 59.4%) in higher percentage 
compared to RAJI cells (35% and 35.9%) most likely reflecting different level of 
LMP1 and LMP2 expression or differences in loop-accessibility.  This requires 
further analysis but is in line with known LMP1 expression levels in different cell 
lines (33). Detection of extracellular domains requires viable cells and low 
temperature incubation to inhibit aggregation and internalization activity.  A 
heterogeneous staining pattern of small patches of FITC-labeled anti-loop 
antibodies was demonstrated in the cell membrane.  Also individual cells among 
the cell population showed a clear distribution (Figure 5).  This corresponds with 
the known heterogeneous expression of LMP1, being abundant in some cells and 
barely detectable in others in the same culture (42). The relation between 
intracellular situated and membrane-associated LMP1 and LMP2 remains to be 
analysed in detail (studies in progress). Conclusion from this study suggests that 
limited humoral immune responses to EBV-encoded tumor antigens LMP1, LMP2 
and BARF1 allow malignant cells to escape from control. Augmentation of immune 
reactivity to EBV-tumor associated antigens especially LMP1 and LMP2, by active 
or passive immunization, may be important to the prevention and treatment of 
NPC as a member of latency type II tumors.  Our finding that immunization of 
rabbits using these peptides can generate highly reactive epitope-specific 
antibodies opens new prospects for immunotherapy and vaccination of patients 
suffering from EBV associated tumors (34).  
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Table 3A. Correlation between LMP1 expression using IHC with IgG reactivity to 
LMP1 recombinant proteins using IFA in NPC patients (n=32)
Table 3B. Correlation between LMP1 expression using IHC with IgG reactivity to
 LMP1 recombinant proteins using IB in NPC patients (n=123)
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